Home > Insider Trading > Filing (0001104659-14-057230)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267813	Marinus Pharmaceuticals Inc	MRNS	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1327625	P L Vii Canaan	285 Riverside Avenue Suite 250 Westport CT 06880		Yes	No	Yes	No
1514133	Canaan Partners Vii Llc	285 Riverside Avenue Suite 250 Westport CT 06880		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-08-05	1,836,398	$0.00	1,836,398	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-08-05	625,000	$8.00	2,461,398	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-08-05	4,742,516	$0.00	729,618	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-08-05	3,838,214	$0.00	590,494	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-08-05	3,355,859	$0.00	516,286	$0.00
Common Stock	Warrants to Purchase Series B Preferred Stock	Disposition	2014-08-05	959,553	$10.86	147,624	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	J	Indirect

Footnotes

Upon the closing of Issuer's initial public offering on August 5, 2014, the preferred stock, which has no expiration date and convertible at any time at the option of the holder, automatically converted, at a conversion ratio of one share of Common Stock for every 6.5 shares of preferred stock, for no additional consideration.
Shares held directly by Canaan VII L.P. (the "Canaan Fund"). Canaan Partners VII LLC ("Canaan VII" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan VII disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of any pecuniary interest therein. Stephen Bloch, a manager of Canaan VII, serves as the representative of the Canaan Entities on the Issuer's board of directors.
This warrant was immediately exercisable. Upon the closing of Issuer's public offering, the warrant was cancelled automatically and for no value in accordance with its terms as it was out-of-the-money..